Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.57 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5730886 | 0.85 | MGLL (0.40) | HTR2CTACR1DRD2CCR2 | |
| SCHEMBL22816650 | 0.81 | HTR2C (0.53) | HTR2CTACR1KDM1ARCOR1 | |
| SCHEMBL8911804 | 0.81 | TACR1 (0.64) | HTR2CTACR1DRD2HTR1AHTR2B | |
| SCHEMBL1065758 | 0.81 | HTR2C (0.77) | HTR2CDRD2HTR1AHTR2BHTR2A | |
| SCHEMBL731682 | 0.80 | ALDH1A1 (0.39) | HTR2CTACR1HTR2BHTR2AKDM1A | |
| SCHEMBL21107854 | 0.80 | HTR2C (0.66) | HTR2CTACR1DRD2HTR1ACCR2 | |
| SCHEMBL14833259 | 0.79 | MGLL (0.44) | HTR2C | |
| SCHEMBL16457233 | 0.77 | HTR2C (0.72) | HTR2CDRD2HTR1AHTR2BHTR2A | |
| SCHEMBL2532290 | 0.77 | HTR2C (0.72) | HTR2CDRD2HTR1AHTR2BHTR2A | |
| SCHEMBL20010986 | 0.77 | SLC6A2 (0.44) | HTR2CDRD2HTR2BHTR2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | HTR2C 4184/4885TACR1 4327/4885DRD2 4417/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | HTR2C 4184/4885TACR1 4327/4885DRD2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.